i agree to the first to market. my thought is how are the trials currently designed? i guess i am being lazy and not looking it up myself. it appears that hh could "fail" if not given at exactly the right time of treatment as this study finds. however, it could succeed really well if given at the right point in treatment. perhaps this is the info dan p was pointing to that roche was waiting for data feedback to design more trials.